Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1990 1
2001 1
2008 1
2009 1
2010 1
2014 2
2016 2
2017 1
2018 1
2021 3
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 20RJ, 5BAuthor
Page 1
German Value Set for the EQ-5D-5L.
Ludwig K, Graf von der Schulenburg JM, Greiner W. Ludwig K, et al. Pharmacoeconomics. 2018 Jun;36(6):663-674. doi: 10.1007/s40273-018-0615-8. Pharmacoeconomics. 2018. PMID: 29460066 Free PMC article.
OBJECTIVES: The objective of this study was to develop a value set for EQ-5D-5L based on the societal preferences of the German population. As the first country to do so, the study design used the improved EQ-5D-5L valuation protocol 2.0 developed by the EuroQol Gro …
OBJECTIVES: The objective of this study was to develop a value set for EQ-5D-5L based on the societal preferences of the German popul …
Predicting Functional Recovery and Quality of Life in Older Patients Undergoing Colorectal Cancer Surgery: Real-World Data From the International GOSAFE Study.
Montroni I, Ugolini G, Saur NM, Rostoft S, Spinelli A, Van Leeuwen BL, De Liguori Carino N, Ghignone F, Jaklitsch MT, Kenig J, Garutti A, Zingaretti C, Foca F, Vertogen B, Nanni O, Wexner SD, Audisio RA; SIOG Surgical Task Force/ESSO GOSAFE Study Group. Montroni I, et al. J Clin Oncol. 2023 Dec 1;41(34):5247-5262. doi: 10.1200/JCO.22.02195. Epub 2023 Jun 30. J Clin Oncol. 2023. PMID: 37390383
Frailty assessment was performed and outcomes, including QoL (EQ-5D-3L) recorded (3/6 months postoperatively). Postoperative FR was defined as a combination of Activity of Daily Living 5 + Timed Up & Go test <20 seconds + MiniCog >2. ...
Frailty assessment was performed and outcomes, including QoL (EQ-5D-3L) recorded (3/6 months postoperatively). Postoperative FR was d …
Quality of Life in Older Adults After Major Cancer Surgery: The GOSAFE International Study.
Montroni I, Ugolini G, Saur NM, Rostoft S, Spinelli A, Van Leeuwen BL, De Liguori Carino N, Ghignone F, Jaklitsch MT, Somasundar P, Garutti A, Zingaretti C, Foca F, Vertogen B, Nanni O, Wexner SD, Audisio RA; SIOG Surgical Task Force/ESSO GOSAFE Study Group. Montroni I, et al. J Natl Cancer Inst. 2022 Jul 11;114(7):969-978. doi: 10.1093/jnci/djac071. J Natl Cancer Inst. 2022. PMID: 35394037 Free PMC article.
Frailty assessment was performed and postoperative outcomes recorded (30, 90, and 180 days postoperatively) together with QoL data by means of the three-level version of the EuroQol five-dimensional questionnaire (EQ-5D-3L), including 2 components: an index (range = 0-1) g …
Frailty assessment was performed and postoperative outcomes recorded (30, 90, and 180 days postoperatively) together with QoL data by means …
Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
Ludwig K, von der Schulenburg JG, Greiner W. Ludwig K, et al. Health Qual Life Outcomes. 2017 Feb 20;15(1):39. doi: 10.1186/s12955-017-0617-9. Health Qual Life Outcomes. 2017. PMID: 28219389 Free PMC article.
BACKGROUND: The EuroQol Group has extended the severity levels of the EQ-5D from three to five (EQ-5D-5L). There are valuation studies worldwide planned in order to convert the EQ-5D-5L health states into a single preference-based summary score based on count …
BACKGROUND: The EuroQol Group has extended the severity levels of the EQ-5D from three to five (EQ-5D-5L). There are valuation …
Safety of ferumoxytol in patients with anemia and CKD.
Singh A, Patel T, Hertel J, Bernardo M, Kausz A, Brenner L. Singh A, et al. Am J Kidney Dis. 2008 Nov;52(5):907-15. doi: 10.1053/j.ajkd.2008.08.001. Epub 2008 Sep 27. Am J Kidney Dis. 2008. PMID: 18824288 Clinical Trial.
SETTING & PARTICIPANTS: 750 patients with CKD stages 1 to 5 and 5D. INTERVENTION: An IV injection of either 17 mL of ferumoxytol or saline placebo over 17 seconds on day 0 and the alternate agent on day 7. ...CONCLUSIONS: Ferumoxytol is well tolerated and has a safety …
SETTING & PARTICIPANTS: 750 patients with CKD stages 1 to 5 and 5D. INTERVENTION: An IV injection of either 17 mL of ferumoxytol …
Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.
Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Provenzano R, et al. Clin J Am Soc Nephrol. 2009 Feb;4(2):386-93. doi: 10.2215/CJN.02840608. Epub 2009 Jan 28. Clin J Am Soc Nephrol. 2009. PMID: 19176796 Free PMC article. Clinical Trial.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a randomized, open-label, controlled, multicenter Phase 3 trial to evaluate the safety and efficacy of intravenous ferumoxytol compared with oral iron. Anemic patients with CKD stage 5D on hemodialysis and on a st …
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a randomized, open-label, controlled, multicenter Phase 3 trial to evaluate the …
Origin of myofibroblasts in the fibrotic liver in mice.
Iwaisako K, Jiang C, Zhang M, Cong M, Moore-Morris TJ, Park TJ, Liu X, Xu J, Wang P, Paik YH, Meng F, Asagiri M, Murray LA, Hofmann AF, Iida T, Glass CK, Brenner DA, Kisseleva T. Iwaisako K, et al. Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):E3297-305. doi: 10.1073/pnas.1400062111. Epub 2014 Jul 29. Proc Natl Acad Sci U S A. 2014. PMID: 25074909 Free PMC article.
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
Mueller V, Wardley A, Paplomata E, Hamilton E, Zelnak A, Fehrenbacher L, Jakobsen E, Curtit E, Boyle F, Harder Brix E, Brenner A, Crouzet L, Ferrario C, Muñoz-Mateu M, Arkenau HT, Iqbal N, Aithal S, Block M, Cold S, Cancel M, Hahn O, Poosarla T, Stringer-Reasor E, Colleoni M, Cameron D, Curigliano G, Siadak M, DeBusk K, Ramos J, Feng W, Gelmon K. Mueller V, et al. Eur J Cancer. 2021 Aug;153:223-233. doi: 10.1016/j.ejca.2021.05.025. Epub 2021 Jun 29. Eur J Cancer. 2021. PMID: 34214937 Free article.
Starting with protocol version 7, the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire and EQ visual analogue scale (VAS) were administered at day 1 of cycle 1, every two cycles during cycles 3-9, every three cycles during cycle 12 and thereafter and at each patient' …
Starting with protocol version 7, the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire and EQ visual analogue scale (VAS) were …
18 results